World Investment Advisors Has $11.78 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

World Investment Advisors grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 66,807 shares of the medical research company's stock after acquiring an additional 6,818 shares during the period. World Investment Advisors' holdings in IQVIA were worth $11,778,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in IQV. Continuum Advisory LLC lifted its stake in IQVIA by 3.7% in the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after buying an additional 64 shares in the last quarter. ST Germain D J Co. Inc. increased its holdings in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the last quarter. Zions Bancorporation N.A. increased its holdings in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in shares of IQVIA by 10.7% during the 4th quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock worth $182,000 after buying an additional 90 shares during the last quarter. Finally, Private Trust Co. NA increased its holdings in shares of IQVIA by 22.4% during the 1st quarter. Private Trust Co. NA now owns 536 shares of the medical research company's stock worth $94,000 after buying an additional 98 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 0.2%

NYSE:IQV traded down $0.41 during mid-day trading on Friday, reaching $164.24. The stock had a trading volume of 674,106 shares, compared to its average volume of 1,653,324. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The stock's 50 day simple moving average is $150.86 and its two-hundred day simple moving average is $173.29. The company has a market capitalization of $28.41 billion, a price-to-earnings ratio of 22.38, a price-to-earnings-growth ratio of 1.82 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. IQVIA's quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.54 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the subject of several research reports. HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and dropped their target price for the company from $260.00 to $160.00 in a report on Friday, April 25th. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Wall Street Zen cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Finally, Mizuho dropped their price target on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $226.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.